PDS Biotechnology Corporation announced that its Key Opinion Leader Roundtable on Addressing Current and Future Treatments for Recurrent/Metastatic Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma and the Potential Application of PDS0101 will now take place on Tuesday, October 3, 2023, from 8:00 – 9:00 AM EDT, due to a scheduling conflict. The event was originally scheduled for Wednesday, September 27, 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PDSB:
- PDS Biotech to Present at the LD Micro Main Event XVI
- PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
- PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- PDS says PDS0202 elicits active neutralization of some influenza strains
- PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
